The relationship between naloxone-induced cortisol and mu opioid receptor availability in mesolimbic structures is disrupted in alcohol dependent subjects

Alcohol

Volumn 46, Issue 6, 2012, Pages 511-517

  Wand, Gary S ^a   Weerts, Elise M ^a   Kuwabara, Hiroto ^a   Wong, Dean F ^a   Xu, Xiaoqiang ^a   McCaul, Mary E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcoholism; Cortisol; HPA axis; Mu Opioid receptors; Naloxone; PET imaging

Indexed keywords

CARFENTANIL C 11; HYDROCORTISONE; MU OPIATE RECEPTOR; NALOXONE; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; ALCOHOLISM; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; FRONTAL CORTEX; FUSIFORM GYRUS; HIPPOCAMPUS; HORMONE RESPONSE; HUMAN; HYPOTHALAMUS; IMAGE ANALYSIS; LIMBIC CORTEX; MALE; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; TEMPORAL CORTEX;

ADULT; ALCOHOLISM; CARBON RADIOISOTOPES; FEMALE; FENTANYL; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; PITUITARY-ADRENAL SYSTEM; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, OPIOID, MU;

EID: 84864519002     PISSN: 07418329     EISSN: 18736823     Source Type: Journal    
DOI: 10.1016/j.alcohol.2012.04.006     Document Type: Article

References (42)

1. al'Absi M., Wittmers L.E., Hatsukami D., Westra R. Blunted opiate modulation of hypothalamic-pituitary-adrenocortical activity in men and women who smoke. Psychosomatic Medicine 2008, 70(8):928-935.
2. Adinoff B., Krebaum S.R., Chandler P.A., Ye W., Brown M.B., Williams M.J. Dissection of hypothalamic-pituitary-adrenal pathology in one-month abstinent alcohol-dependent men: response to CRH and naloxone. Alcoholism: Clinical & Experimental Research 2005, 29:528-537.
3. Borsook D., Hyman S.E. Proenkephalin gene regulation in the neuroendocrine hypothalamus: a model of gene regulation in the CNS. American Journal of Physiology 1995, 269:E393-E408.
4. Bucholz K.K., Cadoret R., Cloninger C.R., Dinwiddie S.H., Hesselbrock V.M., Nurnberger J.I., et al. A new, semi-structured psychiatric interview for use in genetic linkage studies: a report on the reliability of the SSAGA. Journal of Studies on Alcohol 1994, 55(2):149-158.
5. Chen C.P., Kuhn P., Advis J.P., Sarkar D.K. Chronic ethanol consumption impairs the circadian rhythm of pro-opiomelanocortin and period genes mRNA expression in the hypothalamus of the male rat. Journal of Neurochemistry 2004 Mar, 88(6):1547-1554.
6. Dawson D.A. Drinking as a risk factor for sustained smoking. Drug and Alcohol Dependence 2000, 59(3):235-249.
7. Endres C.J., Bencherif B., Hilton J., Madar I., Frost J.J. Quantification of brain mu-opioid receptors with [11C]carfentanil: reference-tissue methods. Nuclear Medicine and Biology 2003 Feb, 30(2):177-186.
8. Frost J.J., Mayberg H.S., Sadzot B., Dannals R.F., Lever J.R., Ravert H.T., et al. Comparison of [11C]diprenorphine and [11C]carfentanil binding to opiate receptors in humans by positron emission tomography. Journal of Cerebral Blood Flow & Metabolism 1990, 10(4):484-492.
9. Genazzani A.R. Central deficiency in beta-endorphin in alcohol addicts. Journal of Clinical Endocrinology & Metabolism 1982, 55:583-586.
10. Gianoulakis C. Characterization of the effects of acute ethanol administration on the release of beta-endorphin peptides by the rat hypothalamus. European Journal of Pharmacology 1990, 180:21-29.
11. Hall F.S., Sora I., Uhl G.R. Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology (Berl) 2001 Feb, 154(1):43-49.
12. Heinz A., Siessmeier T., Wrase J., Buchholz H.G., Gründer G., Kumakura Y., et al. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Archives of General Psychiatry 2005, 62(1):57-64.
13. Hochberg Y., Benjamini Y. More powerful procedures for multiple significance testing. Statistics in Medicine 1990 Jul, 9(7):811-818.
14. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. Journal of Cerebral Blood Flow & Metabolism 2007, 27:1533-1539.
15. Jankord R., Herman J.P. Limbic regulation of hypothalamo-pituitary-adrenocortical function during acute and chronic stress. Annals of the New York Academy of Sciences 2008, 148:64-73.
16. Kinahan P.E., Rogers J.G. Analytic 3D image reconstruction using all detected events. IEEE Transactions on Nuclear Science 1989, 36(1):964-968.
17. Kranzler H.R., Edenberg H.J. Pharmacogenetics of alcohol and alcohol dependence treatment. Current Pharmaceutical Design 2010, 16(19):2141-2148.
18. Leriche M., Méndez M. Ethanol exposure selectively alters beta-endorphin content but not [3H]-DAMGO binding in discrete regions of the rat brain. Neuropeptides 2010, 44(1):9-16.
19. Li X.W., Li T.K., Froehlich J.C. Alcohol alters preproenkephalin mRNA content in the shell and core of the nucleus accumbens. Alcoholism: Clinical & Experimental Research 1996, 20:53-62.
20. Logan J., Fowler J.S., Volkow N., Wolf A., Dewey S., Schlyer D., et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. Journal of Cerebral Blood Flow & Metabolism 1990, 10(5):740-747.
21. McCaul M.E., Wand G.S., Eissenberg T., Rohde C.A., Cheskin L.J. Naltrexone alters the subjective and psychomotor effects of alcohol. Neuropsychopharmacology 2000, 22:480-492.
22. McCaul M.E., Wand G.S., Stauffer R., Lee S.M., Rohde C.A. Naltrexone dampens ethanol-induced cardiovascular and HPA axis activation. Neuropsychopharmacology 2001, 25:537-547.
23. Meltzer C.C., Bryan R.N., Holcomb H.H., Kimball A.W., Mayberg H.S., Sadzot B., et al. Anatomical localization for PET using MR imaging. Journal of Computer Assisted Tomography 1990, 14(3):418-426.
24. Méndez M., Leriche M., Carlos Calva J. Acute ethanol administration transiently decreases [3H]-DAMGO binding to mu opioid receptors in the rat substantia nigra pars reticulata but not in the caudate-putamen. Neuroscience Research 2003, 47(2):153-160.
25. O'Malley S.S., Froehlich J.C. Advances in the use of naltrexone: an integration of preclinical and clinical findings. Recent Developments in Alcoholism 2003, 16:217-245.
26. Oswald L., Wand G. Opioids and alcohol. Physiology & Behavior 2004, 81(2):339-358.
27. Ribeiro S.C., Kennedy S.E., Smith Y.R., Stohler C.S., Zubieta J.K. Interface of physical and emotional stress regulation through the endogenous opioid system and mu-opioid receptors. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2005, 29(8):1264-1280.
28. Sarkar D.K., Kuhn P., Marano J., Chen C., Boyadjieva N. Alcohol exposure during the developmental period induces beta-endorphin neuronal death and causes alteration in the opioid control of stress axis function. Endocrinology 2007, 148(6):2828-2834.
29. Sinha R., O'Malley S.S. Craving for alcohol: findings from the clinic and the laboratory. Alcohol and Alcoholism 1999, 34(2):223-230.
30. Sobell L.C., Sobell M.B. Timeline followback: a technique for assessing self-reported alcohol consumption. Measuring alcohol consumption: Psychosocial and biological methods 1992, 41-72. Humana Press, New Jersey. R.Z. Litten, J. Allen (Eds.).
31. Stephens, M., & Wand, G. (2011). Stress and alcohol use disorders: the role of glucocorticoids. National Institutes of Health's Alcohol Health Research, in press.
32. Sullivan J.T., Sykora K., Schneiderman J., Naranjo C.A., Sellers E.M. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). British Journal of Addiction 1989, 84(11):1353-1357.
33. Swift R.M., Whelihan W., Kuznetsov O. Naltrexone-induced alterations in human ethanol intoxication. American Journal of Psychiatry 1994, 151:1463-1467.
34. Szekely J.L. Opioid peptides and stress. Critical Reviews in Neurobiology 1990, 6:1-12.
35. Titeler M., Lyon R.A., Kuhar M.J., Frost J.F., Dannals R.F., Leonhardt S., et al. Mu opiate receptors are selectively labelled by [3H]carfentanil in human and rat brain. European Journal of Pharmacology 1989, 167(2):221-228.
36. Uhart M., McCaul M.E., Oswald L.M., Choi L., Wand G.S. GABRA6 gene polymorphism and an attenuated stress response. Molecular Psychiatry 2004 Nov, 9(11):998-1006.
37. Wand G.S., Mangold D., Ali M. Adrenocorticotropin response to naloxone in sons of alcohol dependent men. Journal of Clinical Endocrinology & Metabolism 1999, 84:64-68.
38. Wand G.S., Mangold D., El Deiry S., McCaul M.E., Hoover D. Family history of alcoholism and hypothalamic opioidergic activity. Archives of General Psychiatry 1998, 55:1114-1119.
39. Wand G.S., Weerts E.M., Kuwabara H., Frost J.J., Xu X., McCaul M.E. Naloxone-induced cortisol predicts mu opioid receptor binding potential in specific brain regions. Psychoneuroendocrinology 2011, 36(10):1453-1459.
40. Wand, G. S., Weerts, E. M., Kuwabara, H., Wong, D. F., Xu, X., & McCaul, M. E. (2012). The relationship between naloxone-induced cortisol and delta opioid receptor availability in mesolimbic structures is disrupted in alcohol dependent subjects. Addiction Biology, in press.
41. Weerts E.M., Kim Y.K., Wand G.S., Dannals R.F., Lee J.S., Frost J.J., et al. PET imaging of mu- and delta-opioid receptor binding in alcohol dependent and healthy control subjects. Alcoholism: Clinical & Experimental Research 2011, 12:2162-2173.
42. Weerts E.M., Wand G.S., Kuwabara H., Munro C.A., Dannals R.F., Hilton J., et al. Differences in mu- and delta opioid receptor blockade measured by PET in naltrexone-treated recently abstinent alcohol dependent subjects. Neuropsychopharmacology 2008, 33(3):653-665.